CAMBRIDGE, Mass., Dec. 4 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that the company will be
participating at the Harris Nesbitt Gerard Healthcare Conference being held in
New York, NY on December 11, 2003. TKT's presentation will be given by Gregory
D. Perry, Vice President, Finance and Chief Financial Officer at 3:15 p.m.
Eastern Time on Thursday, December 11, 2003 and may be accessed on the
Internet at http://www.tktx.com under the Investor Information section. A replay of
the presentation will be available on TKT's website until December 18, 2003.
About TKT
TKT is a biopharmaceutical company developing therapeutics for the
treatment of rare genetic diseases caused by protein deficiencies. The company
currently markets one product, Replagal(TM) (agalsidase alfa) for the
treatment of Fabry disease in the European Union and certain other countries.
TKT is headquartered in Cambridge, Massachusetts and has a majority-owned
subsidiary in Sweden, TKT Europe-5S AB, which is responsible for European
sales and marketing activities of Replagal. Additional information on TKT is
available on the company's website at http://www.tktx.com.
Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
Contact:
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Specialist of TKT, +1-617-349-0205
|
